Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CALML3 | P27482 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403004 | 1.00 | GPR119 (0.42) | GPR119MAOBKDM4EMAPTTHRB | |
| SCHEMBL6402366 | 0.89 | GPR119 (0.51) | GPR119MAOBMAOAUSP30LMNA | |
| SCHEMBL6402364 | 0.89 | GPR119 (0.51) | GPR119MAOBMAOAUSP30LMNA | |
| SCHEMBL2483101 | 0.88 | MAOA (0.43) | GPR119MAOBMAOASCN9ALMNA | |
| SCHEMBL2499941 | 0.88 | MAOA (0.43) | GPR119MAOBMAOASCN9ALMNA | |
| SCHEMBL6397223 | 0.87 | CALML3 (0.44) | MAOBKDM4EMAPTTHRBMAOA | |
| SCHEMBL6397230 | 0.87 | CALML3 (0.44) | MAOBKDM4EMAPTTHRBMAOA | |
| SCHEMBL6110586 | 0.86 | MAOB (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7489559 | 0.86 | MAOB (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL8017087 | 0.85 | MAOB (0.38) | MAOBMAOASCN9ALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | HUTCHINSON DOUGLAS K (US) | 2005-03-10 | — | — | US | disclosed |
| US-6358942-B1 | MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313307-B1 | DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM | PHARMACIA & UPJOHN COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-0856002-B1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | UPJOHN CO (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6166056-A | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-6051716-A | ANTIMICROBIAL AGENTS | PHARMACIA & UPJOHN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6043266-A | MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| US-5968962-A | ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | CBR1, NCOR1, RCOR1 | GPR119 1593/4885MAOB 2473/4885KDM4E 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.